Efficacy and Safety of BGG492 in the Treatment of Migraine

Summary

This study will assess the efficacy and safety of BGG492 used to treat migraine pain.

Timeline

Start

2009-04

Primary completion

2010-08

Completion

2010-08

Outcome

Missed primary endpoint

paper CONCLUSIONS: Proof-of-concept criterion was not met (≥ 25% BGG492 subjects with a primary response vs placebo at two timepoints). PMID 23963355 ↗

Publications

• Gomez-Mancilla B, Brand R, Jurgens TP, Gobel H, Sommer C, Straube A, Evers S, Sommer M, Campos V, Kalkman HO, Hariry S, Pezous N, Johns D, Diener HC; BGG492 Study Group. Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks. Cephalalgia. 2014 Feb;34(2):103-13. doi: 10.1177/0333102413499648. Epub 2013 Aug 20.

Drugs

Indications